Fluoxetine Hcl Articles
Servier’s Valdoxan superior to Prozac for severe depression in adults
19 September 2009
Lilly's Symbyax is first FDA approved TRD drug
30 March 2009
Lexapro and Zoloft are "best" antidepressants
9 February 2009
Neuropharm autism drug enters EMMA trial
8 December 2008
Australia PBS drug access not yet assured
11 August 2008
Pharma to be creative on generics threat
5 May 2008
Lilly hits back at data suppression claims
28 January 2008
Lilly adds warnings to Zyprexa and Symbyax
15 October 2007
SSRIs lower BMD in men and women
2 July 2007
Mylan gets final OK from FDA for fluoxetine 40mg
11 June 2007
Italy's AIFA justifies Prozac ban for infants
9 April 2007
Light therapy better than Prozac in SAD
14 August 2006
US FDA posts DSOB meeting summary
15 August 2005
Barr Labs profiled by R&M
23 May 2005
EMEA warning over SSRIs, SNRIs in children
26 April 2005
BMJ apologizes to Lilly
31 January 2005
Lilly launches corrective outreach program for Prozac
17 January 2005
Stock Commentary - New York
10 January 2005
BMJ turns over confidential documents to FDA on Lilly's Prozac
10 January 2005
FDA OKs Ranbaxy's generic Prozac
20 December 2004
Editor's views on UK and US news
23 August 2004
Warner Chilcott beats expectations
16 August 2004
EU judge backs Teva's generic Prozac
19 July 2004
Indian firms pay high cost for generics
12 July 2004
Dr Reddy's 3rd-qtr net profit falls 11%
9 February 2004
Generics "can be dearer in Canada than USA"
26 January 2004
UPDATE: Lilly's Zyprexa gets OK from FDA for new use
26 January 2004
Lilly's Zyprexa gets OK from FDA for new use
19 January 2004
Lilly drug cleared for depressive bipolar disease
5 January 2004
Teva stays ahead of the pack with $3.4 billion Sicor acquisition
10 November 2003
Lilly plans major Spanish investment
2 June 2003
Underlying growth beats forecasts at Lilly
28 April 2003
Galen did not tell investors of Sarafem patent row, says CEO
17 February 2003
2003 will fall below forecast, says Eli Lilly
10 February 2003
Dr Reddy's earnings fall on lost exclusivity
10 February 2003
Galen's shares plunge on patent wrangle
13 January 2003
B-MS to withdraw nefazodone in Europe
13 January 2003
Prozac approved for childhood depression
13 January 2003
PBMs fight back: "we cut Rx costs up to 30%"
5 August 2002
Eli Lilly 2nd-qtr sales decrease 9%
29 July 2002
Lilly combination works in bipolar depression
1 July 2002
Lilly's Sarafem cleared for intermittent dosing
24 June 2002
Huge leap in net profit at Dr Reddy's
10 June 2002
Generic success sparks further competition
20 May 2002
Copaxone driving Teva revenue growth
6 May 2002
Stock Commentary - New York
22 April 2002
Antidepressants see "loss of confidence"
4 March 2002
Merck KGaA confident of surviving Glucophage declines
25 February 2002
Watson sees 2001 revenues, income rise
25 February 2002
Interneuron revenues up on Sarafem royalty
25 February 2002
US push for generics of "gold-standard" drugs
25 February 2002
AstraZeneca confident about overcoming loss of Prilosec revenues
11 February 2002
Huge increase in profits at Dr Reddy's
4 February 2002
Barr second-quarter earnings leap on sales of generic Prozac
4 February 2002
FDA generic appros for Watson and Teva
4 February 2002
French study reveals new use for fluoxetine
4 February 2002
Eli Lilly earnings take a tumble
28 January 2002
Lilly settles privacy cases with US govt
28 January 2002
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
Galapagos Genomics and Euroscreen sign GPCR deal
12 December 2001
SPAN seeking US FTC probe of aaiPharma
10 December 2001
Barr Labs raises 2002 earnings estimates
7 December 2001
Tokyo pharma stocks - week to December 3
5 December 2001
Stock Commentary - New York
22 November 2001
US insurer sponsors generics promotion
16 November 2001
Stock Commentary - New York
15 November 2001
Stock Commentary - New York
8 November 2001
Dr Reddy's reports huge rise in profits thanks to generic Prozac
2 November 2001
Stock Commentary - New York
1 November 2001
Eli Lilly adding 5,000 more sales reps
26 October 2001
Glucophage still driving Merck KGaA sales up to record heights
26 October 2001
Stock Commentary - New York
25 October 2001
Xigris still on track for US approval?
23 October 2001
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
